HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha

A method of treating a subject having an inflammatory bowel disease comprising administering an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less, and administering an additional therapeutic agent to the subject, such that treatment of the inflammatory bowel disease is achieved,

• wherein the additional therapeutic agent is selected from the group consisting of a cyclohexane-ylidene derivative, budenoside, epidermal growth factor, a corticosteroid, cyclosporin, sulfasalazine, aminosalicylates, 6-mercaptopurine, azathioprine, metronidazole, lipoxygenase inhibitors, mesalamine, olsalazine, balsalazide, an antioxidant, a thromboxane inhibitor, an IL-1 receptor antagonist, an anti-IL-1β monoclonal antibody, an anti-IL-6 monoclonal antibody, a growth factor, an elastase inhibitor, a pyridinyl-imidazole compound, CDP-571/BAY-10-3356 , cA2, 75 kdTNFR-IgG, 55 kdTNFR-IgG, interleukin-10, IL-4, IL-10 and/or IL-4 agonists, interleukin-11, glucuronide- or dextran-conjugated prodrugs of prednisolone, dexamethasone or budesonide, an ICAM-1 antisense phosphorothioate oligodeoxynucleotide, a soluble complement receptor 1, slow-release mesalazine, methotrexate, an antagonist of Platelet Activating Factor (PAF), ciprofloxacin, and lignocaine.